US 11,864,907 B2
Devices, systems, and methods for monitoring gastrointestinal motility
George Wilfred Duval, Sudbury, MA (US); Bryan Allen Clark, Forest Lake, MN (US); and John Allen Hingston, Framingham, MA (US)
Assigned to Boston Scientific Scimed, Inc., Maple Grove, MN (US)
Filed by Boston Scientific Scimed, Inc., Maple Grove, MN (US)
Filed on Jan. 15, 2019, as Appl. No. 16/247,716.
Claims priority of provisional application 62/617,877, filed on Jan. 16, 2018.
Prior Publication US 2019/0216384 A1, Jul. 18, 2019
Int. Cl. A61B 5/00 (2006.01); A61B 7/00 (2006.01); A61B 5/07 (2006.01)
CPC A61B 5/42 (2013.01) [A61B 5/7264 (2013.01); A61B 7/008 (2013.01); A61B 5/073 (2013.01); A61B 5/7257 (2013.01); A61B 5/7275 (2013.01); A61B 2562/0219 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A method for evaluating a gastrointestinal tract, the method comprising:
receiving an electrical signal obtained by a sensor via at least one lead extension of the sensor positioned proximate to the gastrointestinal tract, the electrical signal including data pertaining to motility in the gastrointestinal tract of a patient;
analyzing a first set of one or more of a plurality of characteristics of the electrical signal relative to a first threshold value indicative of an imminence of a condition of the gastrointestinal tract within a predefined future time frame;
in response to the analyzing of the first set indicating the imminence of the condition, analyzing a second set of one or more of the plurality of characteristics of the electrical signal relative to a second threshold value indicative of a type of the condition to determine the type of the condition, the second set of the one or more of the plurality of characteristics analyzed including a frequency of the electrical signal, to determine the type of the condition as trending toward one of bradygastria or tachygastria, based on measured shifts in the frequency and in response to no obstruction or resting period being determined; and
administering a treatment based on the indicated imminence and the determined type of the condition, the treatment including one or more of neuromodulation or tissue modulation therapy specific to the determined type of the condition.